PSMA

PET/CT MDT Meeting

Date 19/03/2024

Name

D.O.B

ID Number 20041410

Referring Physician Dr Constantinos Zamboglou

Medical History:

Current situation: Re-stagίng after 1st Cycle PSMA-Lu/Ac

2001 Biopsy: confirmation of malignancy (Adeno-Ca of the prostate, Gleason score 5 (2+3) (no report submitted)

2001 2χ Hypethermia as well as diverse alternative treatments

2021 Gradual PSA despite Bicalutamide

05/22 Ga68-PSMA PET/CT (Wiesbaden, Germany): highly ΡSΜΑ expressing prostatic malignancy with SV invasion, and ECE with at least contact ο the anterior rectal wall. Highly PSMA positive pelvic and retroperitoneal LNs, supradiaphragmatic LNs, and multiple bone lesions (Th3, Th12, 7th rib, L5)

05/22 MRI Pelvis: Prostate volume 43cc. PI-RADS V lesion within the posterior ΡΖ extending just above the apex of the prostate.

11/22 PSA 248 ng/ml

11/22 ADT initiation with Goserelin 10.8 mg and Enzalutamide (GOC)

12/22 SBRT of Τ3 spine 30 Gy in 10 Gy

05/23 PSA 80 ng/ml under sufficient testosteron suppresion

08/23 PSA 128 ng/ml under sufficient testosteron suppresion

08/23 PSMA-PET /CT: SD and CR in the prostate and LNs, mixed response in bones with uρ to 5 bone mets in progress

12/23 patients started with abirateron (private)

01-02/24 massive PSA progress >1000 ng/ml

02/23 1st cycle PSMA-Lu/AC + Zoladex in Saarland Germany

Planned

- PSMA-PET before 2nd cycle

- patients wants to ask other Drs if it makes sense to re-start Enza together with the PSMA-Lu/Enza